Degenerative Disc Disease Pipeline Summary

DelveInsight’s, “Degenerative Disc Disease - Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Degenerative Disc Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Degenerative Disc Disease: Understanding

Degenerative Disc Disease: Overview

Degenerative disc disease (DDD) is a chronic spinal disorder characterized by progressive structural and functional deterioration of the intervertebral discs, leading to chronic neck or back pain and impaired mobility. Although termed a "disease," DDD represents an age-related degenerative process that may be accelerated by genetic predisposition, repetitive mechanical loading, obesity, smoking, trauma, and metabolic factors. Degeneration most commonly affects the lumbar and cervical spine, where loss of disc integrity can contribute to disc herniation, spinal stenosis, spondylolisthesis, and chronic low back or neck pain.

Clinical manifestations vary from asymptomatic radiographic degeneration to persistent axial pain, stiffness, muscle spasms, reduced range of motion, and radicular symptoms such as numbness, tingling, or weakness when adjacent nerve roots are compressed. DDD is a leading contributor to disability and healthcare utilization worldwide.

The pathophysiology of DDD involves progressive degradation of the intervertebral disc extracellular matrix, characterized by loss of proteoglycans and water content within the nucleus pulposus, annular fissures, endplate calcification, inflammatory cytokine release, and reduced nutrient diffusion. These changes decrease disc height and biomechanical stability, increasing mechanical stress on the annulus fibrosus, facet joints, ligaments, and surrounding musculature. Inflammatory mediators such as IL-1?, TNF-?, and matrix metalloproteinases (MMPs) promote extracellular matrix breakdown and may stimulate nerve and blood vessel ingrowth into normally aneural disc tissue, contributing to chronic pain.

Diagnosis is based on clinical history and physical examination, supported by magnetic resonance imaging (MRI), which remains the gold standard for evaluating disc degeneration, disc height loss, Modic changes, annular tears, and neural compression. Additional investigations, including radiography, computed tomography (CT), or electrodiagnostic studies, may be performed when instability, bony abnormalities, or radiculopathy is suspected.

Management of DDD emphasizes a multimodal, conservative approach aimed at reducing pain, restoring function, and preventing disability. First-line treatment includes structured physical therapy, exercise programs, patient education, weight management, smoking cessation, and ergonomic modifications to improve spinal biomechanics. Pharmacological therapies include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, selected muscle relaxants, duloxetine, or short-term analgesics, while epidural steroid injections or facet interventions may provide temporary relief in carefully selected patients. Surgical options, including spinal fusion or total disc replacement, are reserved for patients with persistent disabling pain or neurological deficits who fail comprehensive conservative treatment. Emerging regenerative therapies, including mesenchymal stem cells, growth factors, gene therapy, and biomaterial-based disc repair, are under active investigation to restore disc structure and function rather than simply alleviating symptoms.

"Degenerative Disc Disease- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Degenerative Disc Disease pipeline landscape is provided which includes the disease overview and Degenerative Disc Disease treatment guidelines. The assessment part of the report embraces, in depth Degenerative Disc Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Degenerative Disc Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Degenerative Disc Disease R&D. The therapies under development are focused on novel approaches to treat/improve Degenerative Disc Disease.

Degenerative Disc Disease Emerging Drugs Chapters

This segment of the Degenerative Disc Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Degenerative Disc Disease Emerging Drugs

BRTX-100: BioRestorative Therapies

BRTX-100 is an investigational autologous cell therapy consisting of hypoxia-cultured bone marrow-derived mesenchymal stem cells (MSCs) enriched with autologous platelet lysate, designed for intradiscal injection into degenerated lumbar discs. It aims to promote disc repair, reduce inflammation, and alleviate chronic discogenic low back pain by restoring the damaged disc microenvironment. BRTX-100 is being evaluated as a single-dose, minimally invasive treatment for patients with chronic lumbar degenerative disc disease who have not responded to conservative therapies. The therapy is currently under investigation in a randomized, double-blind Phase II clinical trial assessing its safety and preliminary efficacy.

CBT005: Cartago Biotech Pty Ltd

CBT005 is an investigational recombinant human Growth Differentiation Factor-6 (rhGDF-6) biologic administered as a single intradiscal injection for the treatment of lumbar degenerative disc disease. It is designed to stimulate the body's own stem cells, promote regeneration of intervertebral disc tissue, restore disc structure, and stabilize the spine, thereby addressing the underlying pathology rather than only relieving symptoms. CBT005 is intended as a minimally invasive alternative to spinal surgery for patients with chronic discogenic low back pain caused by disc degeneration. The therapy is currently being evaluated in an open-label Phase I/II clinical trial to assess its safety, tolerability, dose, and preliminary efficacy in adults with lumbar degenerative disc disease.

Further product details are provided in the report……..

Degenerative Disc Disease: Therapeutic Assessment

This segment of the report provides insights about the different Degenerative Disc Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Degenerative Disc Disease
• There are approx. 15+ key companies which are developing the therapies for Degenerative Disc Disease. The companies which have their Degenerative Disc Disease drug candidates in the mid stage, i.e. Phase II include, BioRestorative Therapies.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Degenerative Disc Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Degenerative Disc Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Degenerative Disc Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Degenerative Disc Disease drugs.

Degenerative Disc Disease Report Insights

• Degenerative Disc Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Degenerative Disc Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Degenerative Disc Disease drugs?
• How many Degenerative Disc Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Degenerative Disc Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Degenerative Disc Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Degenerative Disc Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BioRestorative Therapies
• Cartago Biotech Pty Ltd
• Kolon TissueGene, Inc.
• DiscGenics
• Creative Medical Technology Holdings
• EicOsis Human Health Inc.
• FibroBiologics

Key Products

• BRTX-100
• CBT005
• TG-C
• IDCT
• CELZ-201-DDT
• EC5026
• CybroCell